Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples